Rhofade FDA Approval History
FDA Approved: Yes (First approved January 18, 2017)
Brand name: Rhofade
Generic name: oxymetazoline hydrochloride
Dosage form: Cream
Company: Allergan plc
Treatment for: Rosacea
Rhofade (oxymetazoline hydrochloride) is a topical alpha1A adrenoceptor agonist vasoconstrictor for the treatment of persistent facial erythema associated with rosacea in adults.
Development timeline for Rhofade
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.